NAS10028,437+0.91%S&P7,689+1.58%GOLD$4,138+1.59%BTC$79,577−1.03%VIX16.77+0.96%latest tape · as of 14:03 UTC
The Screen · Consumer Defensive · Education & Training Services
IHiHuman Inc ADR
IH · the NYSE · USD · Market cap $70M · 558 employees
iHuman Inc., together with its subsidiaries, provides an integrated suite of tech-powered intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China.
FAIL · Does not pass the screen
1.14 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 14:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price1.14 USD at the 4 Nov 2026 close
Fair value1.40. Our model only; no analyst estimate to cross-check.
Our value readUndervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price1.14 USD
Fair value1.40Our model only; no analyst estimate to cross-check.
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-16Read Accumulation1.19-4.2% to today Markdown gives way to Accumulation
2026-10-02Read Markdown1.15-0.9% to today ✓Distribution gives way to Markdown after a 16% slide in 13 weeks
2026-07-02Read Distribution1.38-17.1% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
iHuman Inc ADR holds its Accumulation at $1.14. The statistical read favours the buyers, held for 10 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 10 days
Price at the screen
$1.14
Valuation
N/A trailing · 6.05 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.11
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.83%
Below 33%
Interest-bearing debt is just 0.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
87.56%
Below 49%
Money owed to the company is 87.6% of assets, above the 49% limit.
Fail
Revenue purity
2.80%
Below 5%
Only 2.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
iHuman's business is fine, but its receivables are about 88% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IH's ethical verdict changes
Today IH does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 17% discount to our $1.40 fair value, none competitive moat.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 18.6% discount to the base estimate.
Where our models see it going: fair-value estimate $1.40, with a range of $1.40 to $2.32, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
Trading at 6.1x forward earnings, with a none competitive moat. That is a 17% discount to our $1.40 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IH trades on the NYSE (the company is based in China). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$1.14-4.2%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-10-16Accumulation · changed$1.19+3.5%Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-10-02Markdown · changed$1.15-16.1%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%. Since the last review it its composite score rose.
2026-09-01Distribution$1.37+0.0%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-08-02Distribution$1.37-0.4%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-18Distribution$1.38+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-03Distribution$1.38+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$1.38Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.